CL2012001725A1 - Procesos para la preparacion de 2-(6-fluoro-1h-indol-3-il)etanamina, a partir de (6-fluoro-1h-indol-3-il)acetonitrilo y un catalizador de metal de transicion en un solvente alcoholico, posteriormente hidrogenar la mezcla con h2. - Google Patents

Procesos para la preparacion de 2-(6-fluoro-1h-indol-3-il)etanamina, a partir de (6-fluoro-1h-indol-3-il)acetonitrilo y un catalizador de metal de transicion en un solvente alcoholico, posteriormente hidrogenar la mezcla con h2.

Info

Publication number
CL2012001725A1
CL2012001725A1 CL2012001725A CL2012001725A CL2012001725A1 CL 2012001725 A1 CL2012001725 A1 CL 2012001725A1 CL 2012001725 A CL2012001725 A CL 2012001725A CL 2012001725 A CL2012001725 A CL 2012001725A CL 2012001725 A1 CL2012001725 A1 CL 2012001725A1
Authority
CL
Chile
Prior art keywords
indol
fluoro
processes
preparation
ethanamine
Prior art date
Application number
CL2012001725A
Other languages
English (en)
Inventor
Frans Therkelsen
Michael Harold Rock
Svend Treppendahl
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2012001725A1 publication Critical patent/CL2012001725A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

SE REVELAN AQUÍ LOS PROCESOS PARA LA PREPARACIÓN DE UN AGENTE FARMACÉUTICAMENTE<br /> ACTIVO Y LAS SALES FARMACÉUTICAMENTE ACEPTABLES DEL MISMO
CL2012001725A 2009-12-23 2012-06-22 Procesos para la preparacion de 2-(6-fluoro-1h-indol-3-il)etanamina, a partir de (6-fluoro-1h-indol-3-il)acetonitrilo y un catalizador de metal de transicion en un solvente alcoholico, posteriormente hidrogenar la mezcla con h2. CL2012001725A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28953009P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
CL2012001725A1 true CL2012001725A1 (es) 2012-11-30

Family

ID=43567689

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001725A CL2012001725A1 (es) 2009-12-23 2012-06-22 Procesos para la preparacion de 2-(6-fluoro-1h-indol-3-il)etanamina, a partir de (6-fluoro-1h-indol-3-il)acetonitrilo y un catalizador de metal de transicion en un solvente alcoholico, posteriormente hidrogenar la mezcla con h2.

Country Status (37)

Country Link
US (3) US8461353B2 (es)
EP (1) EP2516394B1 (es)
JP (2) JP5864435B2 (es)
KR (2) KR101873182B1 (es)
CN (2) CN102656146B (es)
AR (1) AR079580A1 (es)
AU (1) AU2010335659B2 (es)
BR (1) BR112012015749A2 (es)
CA (1) CA2785440C (es)
CL (1) CL2012001725A1 (es)
CR (1) CR20120316A (es)
CY (1) CY1118032T1 (es)
DK (1) DK2516394T3 (es)
DO (1) DOP2012000170A (es)
EA (1) EA021440B1 (es)
ES (1) ES2575666T3 (es)
GE (1) GEP20146078B (es)
HK (2) HK1174921A1 (es)
HR (1) HRP20160518T1 (es)
HU (1) HUE028806T2 (es)
IL (2) IL220329A (es)
MA (1) MA33945B1 (es)
ME (1) ME02401B (es)
MX (1) MX2012007078A (es)
MY (1) MY159251A (es)
NZ (2) NZ600639A (es)
PL (1) PL2516394T3 (es)
PT (1) PT2516394E (es)
RS (1) RS54820B1 (es)
SG (1) SG181910A1 (es)
SI (1) SI2516394T1 (es)
SM (1) SMT201600166B (es)
TN (1) TN2012000279A1 (es)
TW (1) TW201139370A (es)
UA (1) UA111584C2 (es)
WO (1) WO2011076212A2 (es)
ZA (1) ZA201305936B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
CN104130174A (zh) * 2014-07-30 2014-11-05 天津市斯芬克司药物研发有限公司 一种吲唑衍生物及其制备方法
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
TW201630881A (zh) 2014-12-12 2016-09-01 Ｈ 朗德貝克公司 用於生產艾達魯吡啶之方法
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
MA41148A (fr) * 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
CN108271369A (zh) * 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
JP2019513742A (ja) 2016-04-08 2019-05-30 ハー・ルンドベック・アクチエゼルスカベット イミンの水素化によるイダロピルジンの製造方法
EP3333154A1 (en) * 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042685A (en) 1962-07-03 Process of making g-fluoro tryptamine
GB846675A (en) 1958-04-18 1960-08-31 Lab Francais Chimiotherapie Process for the production of a tryptamine derivative
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
DE69416697T2 (de) 1993-12-28 1999-09-09 Rhone Poulenc Fibres Verfahren zur katalytischer hydrogenierung von nitrilen zu aminen in anwesenheit eines dosierten raney nickel katalysators
EP0737101B1 (fr) 1993-12-28 1998-09-23 RHODIA FIBER &amp; RESIN INTERMEDIATES Procede de preparation d'un catalyseur d'hydrogenation de nitriles en amines et application de ce catalyseur en hydrogenation
US5869653A (en) 1997-10-30 1999-02-09 Air Products And Chemicals, Inc. Hydrogenation of nitriles to produce amines
KR20000069831A (ko) 1997-10-31 2000-11-25 요트.게.아. 롤페즈 구성 신호에 대한 잡음 추가를 통한 엘피씨 원칙에 따라 인코딩된 음성의 오디오 표현을 위한 방법 및 장치
US6156694A (en) 1998-11-05 2000-12-05 E. I. Dupont De Nemours & Company Raney cobalt catalyst and a process for hydrogenating organic compounds using said catalyst
AU2002303094B2 (en) 2001-03-29 2006-11-23 Eli Lilly And Company N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
US7084154B2 (en) * 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
FR2866335B1 (fr) 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
JP2006169113A (ja) * 2004-12-10 2006-06-29 Dainippon Sumitomo Pharma Co Ltd インドール類の合成方法および合成中間体
WO2007070796A1 (en) * 2005-12-15 2007-06-21 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
CN101531624A (zh) 2009-04-08 2009-09-16 大连凯飞精细化工有限公司 6-氟吲哚-3-乙腈的合成方法
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent

Also Published As

Publication number Publication date
MY159251A (en) 2016-12-30
DK2516394T3 (en) 2016-06-13
US20150080584A1 (en) 2015-03-19
KR101796330B1 (ko) 2017-11-09
EP2516394B1 (en) 2016-03-16
ME02401B (me) 2016-09-20
TW201139370A (en) 2011-11-16
US20110152539A1 (en) 2011-06-23
NZ600639A (en) 2014-07-25
SI2516394T1 (sl) 2016-07-29
IL220329A (en) 2016-03-31
KR20170125417A (ko) 2017-11-14
PL2516394T3 (pl) 2016-09-30
CN103694161A (zh) 2014-04-02
GEP20146078B (en) 2014-04-10
HUE028806T2 (en) 2017-01-30
CA2785440C (en) 2018-05-01
JP6195605B2 (ja) 2017-09-13
CY1118032T1 (el) 2017-05-17
DOP2012000170A (es) 2012-08-31
RS54820B1 (sr) 2016-10-31
US20130245281A1 (en) 2013-09-19
AU2010335659B2 (en) 2015-05-21
PT2516394E (pt) 2016-06-07
CA2785440A1 (en) 2011-06-30
EA201290552A1 (ru) 2012-12-28
WO2011076212A3 (en) 2011-08-11
US8461353B2 (en) 2013-06-11
HK1174921A1 (en) 2013-06-21
EA021440B1 (ru) 2015-06-30
SG181910A1 (en) 2012-08-30
JP5864435B2 (ja) 2016-02-17
CN102656146B (zh) 2014-12-17
AU2010335659A1 (en) 2012-07-05
KR101873182B1 (ko) 2018-06-29
KR20120112480A (ko) 2012-10-11
HRP20160518T1 (hr) 2016-06-03
IL231141A (en) 2016-03-31
ES2575666T3 (es) 2016-06-30
MA33945B1 (fr) 2013-01-02
IL231141A0 (en) 2014-03-31
WO2011076212A2 (en) 2011-06-30
CN103694161B (zh) 2015-09-09
CN102656146A (zh) 2012-09-05
TN2012000279A1 (en) 2013-12-12
US9382205B2 (en) 2016-07-05
JP2016117734A (ja) 2016-06-30
ZA201305936B (en) 2015-09-30
UA111584C2 (uk) 2016-05-25
BR112012015749A2 (pt) 2015-09-15
IL220329A0 (en) 2012-08-30
CR20120316A (es) 2012-08-16
SMT201600166B (it) 2016-07-01
US8901318B2 (en) 2014-12-02
NZ625798A (en) 2014-10-31
JP2013515683A (ja) 2013-05-09
EP2516394A2 (en) 2012-10-31
MX2012007078A (es) 2012-07-20
HK1196352A1 (en) 2014-12-12
AR079580A1 (es) 2012-02-01

Similar Documents

Publication Publication Date Title
CL2012001725A1 (es) Procesos para la preparacion de 2-(6-fluoro-1h-indol-3-il)etanamina, a partir de (6-fluoro-1h-indol-3-il)acetonitrilo y un catalizador de metal de transicion en un solvente alcoholico, posteriormente hidrogenar la mezcla con h2.
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
AR053605A1 (es) Aparato y metodo para establecer un conjunto activo de portadoras para un receptor
CL2013001876A1 (es) Compuesto para la modificación reversible de una poliamina activa en membrana anfifática; polímero de suministro para suministrar un polinecleotido de interferencia de arn (iarn) a una célula in vivo; uso de un iarn con un polimero de suministro.
ECSP10010184A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril-urea
NO20083462L (no) Nye tiofenderivater som S1P1/EDG1-reseptoragonister
CL2011001992A1 (es) Proceso para producir 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina que comprende la etapa de precipitar el solvato isopropanol bromhidrato del compuesto a partir de un solvente con mas de 65% (v/v) de isopropanol; proceso de purificacion; y el intermediario solvato isopropanol bromhidrato del compuesto.
MX341200B (es) Composicion farmaceutica de disolucion rapida.
CO6480977A2 (es) Agonistas de gpr119
EA200901563A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
ECSP11011245A (es) Novedosos herbicidas
RS53586B1 (en) DERIVATION OF DECISION
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
CR10286A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
JO3112B1 (ar) تركيبة دوائية سريعة التحلل
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
BR112012000501A2 (pt) eletrodo, método para formar um eletrodo para transferência de fase eletroquímica, dispositivo e método para executar transferência de fase eletroquímica, e, dispositivo para transferência de fase eletroquímica.
ITMI20100233A1 (it) Procedimento di produzione di supporto di dialcossimagnesio per catalizzatore per la polimerizzazione di olefine, procedimento di produzione di catalizzatore per la polimerizzazione di olefine impiegante il medesimo e procedimento di polimerizzazione
CL2011001862A1 (es) Composicion formadora de espuma que comprende una mezcla de cis-1,1,1,4,4,4-hexafluoro 2-buteno y 1,1,1,3,3 pentafluoropropano y un compuesto que contiene hidrogeno activo; espuma de polimero formada a partir de dicha composicion; y su proceso de produccion.
BR112012019866A2 (pt) composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um composto
WO2014210436A3 (en) Kappa opioid agonists and uses thereof
BR112012005938A2 (pt) formas de dosagem, e, processo para produzir preparações para formas de dosagem de ingredientes ativos de baixa solubilidade em água
CL2012000777S1 (es) Generador eolico de base tronco conico invertido de manto convexo, y manto semicilindrico hueco superior, abombado, horizontal y abierto en las bases; posee porcion esferica frontal con cilindros laterales, y saliente oblicua posterior, con paletas lanceoladas iguales, con una cara concava y la opuesta convexa, y extremo convexo.
UY34170A (es) Formas cristalinas de 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida
HK1154032A1 (en) A process for the ultrapurification of alginates